繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

哈罗公学重申2025年收入前景为2.7亿至2.8亿美元,得益于扩大商业足迹和投资组合绩效

2026-02-02 20:15

  • Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to  the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding
  • OneHarrow Initiative is Launched to Unify Branding under Harrow
  • Patrick W. Sullivan Promoted to Serve as Harrow's Chief Commercial Officer
  • MELT-300 and MELT-210 Programs on Track for New Drug Application Filings
  • Harrow's ImprimisRx Settles Pending Regulatory Matters with the California Board of Pharmacy

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。